Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.50 |
| ▸ | AXL | P30530 | 1/20 | 0.47 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.42 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.42 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.42 |
| ▸ | ROS1 | P08922 | 1/20 | 0.42 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30368877 | 1.00 | KDM4E (0.59) | KDM4ELMNACYP3A4CYP2D6CYP1A2 | |
| SCHEMBL28109084 | 0.98 | KDM4E (0.57) | KDM4ELMNACYP3A4CYP2D6CYP1A2 | |
| SCHEMBL30343676 | 0.83 | TNF (0.53) | KDM4ELMNACYP3A4CYP2D6CYP1A2 | |
| SCHEMBL197053 | 0.83 | TNF (0.53) | KDM4ELMNACYP3A4CYP2D6CYP1A2 | |
| SCHEMBL28013422 | 0.81 | TNF (0.52) | KDM4ELMNACYP3A4CYP2D6CYP1A2 | |
| Ammonia Solution, Strong SCHEMBL28213837 | 0.81 | TNF (0.52) | KDM4ELMNACYP3A4CYP2D6CYP1A2 | |
| Ammonia Solution, Strong SCHEMBL28213840 | 0.79 | TNF (0.50) | KDM4ELMNACYP3A4CYP2D6CYP1A2 | |
| SCHEMBL6212179 | 0.79 | MAPT (0.52) | KDM4ELMNACYP3A4CYP2D6CYP1A2 | |
| SCHEMBL6065407 | 0.77 | CYP3A4 (0.72) | KDM4ELMNACYP3A4CYP2D6CYP1A2 | |
| SCHEMBL6240424 | 0.77 | LMNA (0.63) | KDM4ELMNACYP3A4CYP2D6CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108752274-B | Preparation method of 5-isoquinoline sulfonyl chloride | 遂成药业股份有限公司 | 2022-03-29 | — | — | CN | claimed |
| CN-114014858-A | Process for preparing polysubstituted indolizine derivatives | 淮阴师范学院 | 2022-02-08 | — | — | CN | claimed |
| US-10125226-B2 | Scale-up process of bifunctionalized triblock copolymers with secondary and tertiary amines, with application in dewatering and desalting of heavy crude oils | INSTITUTO MEXICANO DEL PETROLEO (MX) | 2018-11-13 | — | — | US | claimed |
| CN-108752274-A | A kind of preparation method of 5- isoquinoline sulfonyl chlorides | 遂成药业股份有限公司 | 2018-11-06 | — | — | CN | claimed |
| CN-105753838-A | Novel high-regioselectivity amination method of quinoline derivatives | 安阳师范学院 | 2016-07-13 | — | — | CN | claimed |
| US-20140364566-A1 | SCALE-UP PROCESS OF BIFUNCTIONALIZED TRIBLOCK COPOLYMERS WITH SECONDARY AND TERTIARY AMINES, WITH APPLICATION IN DEWATERING AND DESALTING OF HEAVY CRUDE OILS | INSTITUTO MEXICANO DEL PETROLEO (MX) | 2014-12-11 | — | — | US | claimed |
| WO-2014179528-A2 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS INCLUDING SUBSTITUTED NAPHTHALIMIDES SUCH AS AMONAFIDE FOR THE TREATMENT OF IMMUNOLOGICAL, METABOLIC, INFECTIOUS, AND BENIGN OR NEOPLASTIC HYPERPROLIFERATIVE DISEASE CONDITIONS | BROWN DENNIS M (US) | 2014-11-06 | — | — | WO | claimed |
| EP-1089976-B1 | METHOD OF PREPARING 5- OR 8-BROMOISOQUINOLINE DERIVATIVES | NEUROSEARCH AS (DK) | 2003-09-24 | — | — | EP | claimed |
| EP-3710428-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2026-03-25 | — | — | EP | disclosed |
| US-12552830-B2 | Steroidal compound derivatives as therapeutic agents | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2026-02-17 | — | — | US | disclosed |
| US-12441708-B2 | Cereblon ligands and bifunctional compounds comprising the same | ARVINAS OPERATIONS, INC. (US) | 2025-10-14 | — | — | US | disclosed |
| US-20250312347-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | BROWN DENNIS M (US) | 2025-10-09 | — | — | US | disclosed |
| US-20250313547-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | ARVINAS OPERATIONS INC (US) | 2025-10-09 | — | — | US | disclosed |
| EP-4613745-A2 | PROCESS FOR PREPARING A COT INHIBITOR COMPOUND | Gilead Sciences, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-0172427-B1 | PROCESS FOR PRODUCTION OF VINYL CHLORIDE POLYMER | Shin-Etsu Chemical Co., Ltd. (JP) | 1989-07-05 | — | — | EP | disclosed |
| US-4758639-A | Process for production of vinyl polymer | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 1988-07-19 | — | — | US | disclosed |
| US-4757124-A | Suspension or emulsion polymerizing vinyl chloride monomer or mixture of vinyl chloride with vinyl monomer copolymerizable therewith in reactor with walls coated with antiscaling compound containing dye or pigments | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 1988-07-12 | — | — | US | disclosed |
| EP-0172427-A2 | Process for production of vinyl chloride polymer | Shin-Etsu Chemical Co., Ltd. (JP) | 1986-02-26 | — | — | EP | disclosed |
| US-4396619-A | ANTIBIOTICS | ELI LILLY AND COMPANY (US) | 1983-08-02 | — | — | US | disclosed |
| US-4382932-A | Isoquinolinium substituted cephalosporins | ELI LILLY AND COMPANY (US) | 1983-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250312347-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | UNG, DPYD, TPMT | KDM4E 714/4885LMNA 4710/4885CYP3A4 1288/4885 |
| US-20250313547-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | CRBN, CBL, MDM2 | KDM4E 1613/4885LMNA 3085/4885CYP3A4 4541/4885 |
| US-12552830-B2 | Steroidal compound derivatives as therapeutic agents | PGF, NR3C2, NR5A1 | KDM4E 3882/4885LMNA 1575/4885CYP3A4 738/4885 |
| US-12441708-B2 | Cereblon ligands and bifunctional compounds comprising the same | CRBN, CBL, MDM2 | KDM4E 1613/4885LMNA 3085/4885CYP3A4 4541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.